drugset / Trial / NCT06403501

Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris

NCT06403501

Phase 3 Recruiting 692 enrolled Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to determine the safety and efficacy of clascoterone cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.

Timeline

Start
2024-05-20
Primary completion
2026-10
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Clascoterone Small molecule 1 % Topical

Indications